Sprout AI LOGO.jpg
Sprout AI Inc. Announces Initial Sales Order
September 21, 2021 08:30 ET | Sprout AI Inc.
VANCOUVER, British Columbia, Sept. 21, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Sprout AI Inc. (“Sprout AI” or the “Company”) (CSE: SPRT) is a technologically focused, sustainable vertical...
AlliendCorp_logo.png
Allied Corp. Advances Psilocybin Product Psilonex™ RX and Initiates Manufacturing Process
September 10, 2021 08:55 ET | Allied Corp.
KELOWNA, British Columbia, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce that it has initiated the manufacturing activities for...
OH_Logo.png
Optimi Health Appoints New Chief Executive Officer
August 31, 2021 09:00 ET | Optimi Health Corp.
VANCOUVER, British Columbia, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional...
87520785_101152591495741_6497961433500745728_o.jpg
Mycotopia Therapies Signs Agreement With Havn Life Sciences For Purchase of Psilocybin SPP
August 25, 2021 08:00 ET | Mycotopia Therapies Inc.
MIAMI, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Mycotopia Therapies, Inc. (OTC Pink: TPIA) (the “Company”), a company focused on psychedelic therapies, announced today it has entered into a Psilocybin...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs’ Clinics Submit Application to Treat Patient With Psilocybin Psychedelic-Assisted Therapy
August 13, 2021 02:55 ET | Core One Labs Inc.
VANCOUVER, British Columbia, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (the “Company”) a research and technology company focused...
New poll shows a strong base of Canadians overwhelmingly support controlled legal access to psilocybin-assisted therapy; Canadian Psychedelic Association responds with Memorandum of Regulatory Approval (MORA)
August 04, 2021 07:02 ET | Canadian Psychedelic Association
Vancouver, BC, Aug. 04, 2021 (GLOBE NEWSWIRE) -- A Nanos Research Survey released today by the Canadian Psychedelic Association (CPA) shows 82 percent of Canadians approve the use of...
ibn-iw-globe-2.png
InvestorBrandNetwork Announces The Dealmaker Show Interview with Tryp Therapeutics Inc. CEO Greg McKee
August 03, 2021 08:00 ET | InvestorBrandNetwork (IBN)
LOS ANGELES, Aug. 03, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces...
Picture1.jpg
Mark Haden, Psychedelic Medicine Expert, Joins Clearmind Medicine’s Advisory Board
August 03, 2021 07:00 ET | Clearmind Medicine
Toronto, Aug. 03, 2021 (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of...
trypf.png
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Exploring Psilocybin Treatments in Underserved Indications
July 30, 2021 08:30 ET | Tryp Therapeutics Inc.
NEW YORK, July 30, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces the availability of a broadcast titled, “Psychedelics — Not Just for Mental...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One’s Dr. Robert E.W. Hancock to Host Virtual Townhall Webcast and Present on Proprietary Biosynthesized Psilocybin Wednesday, August 4, 2021
July 30, 2021 03:10 ET | Core One Labs Inc.
VANCOUVER, British Columbia, July 30, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that...